 |
|
Oxford Genome's latest funding
Oxford Genome Sciences, a developer of personalised medicines, has completed its third fundraising in as many years as it continues the development of its cancer and Alzheimer’s disease therapies.
The undisclosed funding was arranged and managed by the South East Growth Fund (SEGF), which is making its third investment in the company. Other funders included existing investor Oxford Capital Partners with Catapult Growth Fund making the first investment from its new £30 million fund.
SEGF was led by principal Jason Gould, who said: “We supported this company in its infancy and are thrilled that it has developed into such an important business.
“This funding round provides an excellent platform from which the company can continue its rapid expansion and provide evidence of substantial cash reserves and corporate visibility to its long-term biotech/pharma partners,” he added.
People also read ... |
Related Articles |
Interesting links
Other Sector Watch
- Investment veteran airs fears over UK biotech Oct 21 2008
- Talking rubbish Jul 28 2008
- Crisis?– what crisis? Jul 01 2008
- Let the
drilling begin
May 13 2008 - Bargains on the high street
Mar 13 2008
M&A News
- Corporates idealistic about M&A Dec 02 2008
- Conference takes M&A global Dec 02 2008
- RedHot Media buys AllChina advertising stake Dec 02 2008
- ESI Group’s US software deal Dec 01 2008
- Adecco takes controlling stake in DNC Dec 01 2008
Special Offers
- 2008 AIM Guide: Jul 17 2007
- Growth Company Investor Magazine: Jul 17 2007
- Cash Shells 2007 - Research report Jul 17 2007
- Venture Capital Trusts Jul 04 2007
M&A Deals
- IMS Maxims acquires CSW assets Dec 02 2008
- Ultra Electronics gains MidEast foothold Dec 01 2008
- Commoditrade takes control of AMCO Dec 01 2008
- Moto picks up Roadchef site Nov 28 2008
- Accessories 4 Technology's £4m boost Nov 28 2008
Business Diary
- M&A Expanding internationally 27th November
- Rosenblatt New Energy Awards 2009 25th February